Achieve Life Sciences, Inc. (ACHV)

NASDAQ: ACHV · IEX Real-Time Price · USD
4.420
+0.370 (9.14%)
Mar 1, 2024, 4:00 PM EST - Market closed
9.14%
Market Cap 93.55M
Revenue (ttm) n/a
Net Income (ttm) -35.57M
Shares Out 21.17M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 177,944
Open 4.050
Previous Close 4.050
Day's Range 3.930 - 4.440
52-Week Range 3.030 - 10.300
Beta 1.45
Analysts Strong Buy
Price Target 18.50 (+318.55%)
Earnings Date Mar 14, 2024

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO John A. Bencich M.B.A.
Employees 20
Stock Exchange NASDAQ
Ticker Symbol ACHV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price forecast is $18.5, which is an increase of 318.55% from the latest price.

Price Target
$18.5
(318.55% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025 Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025

3 days ago - GlobeNewsWire

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants

3 days ago - GlobeNewsWire

Achieve Life Sciences shares drop as analysts see delayed launch of smoking-cessation treatment

Achieve Life Sciences Inc. shares ACHV, -1.09% dropped 25% premarket on Tuesday as analysts forecasted delays in the launch of the company's smoking cessation treatment cytisinicline. In a recent meet...

2 months ago - Market Watch

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comme...

2 months ago - GlobeNewsWire

Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023

SEATTLE and VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development ...

4 months ago - GlobeNewsWire

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development...

6 months ago - GlobeNewsWire

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV)...

7 months ago - GlobeNewsWire

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development ...

7 months ago - GlobeNewsWire

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability”

8 months ago - GlobeNewsWire

Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results

Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine dependence achieved positive results, showing a stat...

10 months ago - Market Watch

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo

10 months ago - GlobeNewsWire

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commer...

10 months ago - GlobeNewsWire

Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update

SEATTLE and VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commer...

10 months ago - GlobeNewsWire

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development...

11 months ago - GlobeNewsWire

Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference

SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and comm...

11 months ago - GlobeNewsWire

Achieve Life Sciences Announces Refresh to Board of Directors

SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development a...

1 year ago - GlobeNewsWire

Achieve Life Sciences Announces Granting of New Hire Inducement Award

SEATTLE, Wash. and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development a...

1 year ago - GlobeNewsWire

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

Company to host conference call March 16, 2023, at 4:30 PM EDT Company to host conference call March 16, 2023, at 4:30 PM EDT

1 year ago - GlobeNewsWire

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

Topline Data Expected in 2Q 2023 Topline Data Expected in 2Q 2023

1 year ago - GlobeNewsWire

Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global deve...

1 year ago - GlobeNewsWire

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development...

1 year ago - GlobeNewsWire

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...

1 year ago - GlobeNewsWire

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States ORCA-3 Designed ...

1 year ago - GlobeNewsWire

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, August 11, 2022 Company to host conference call at 4:30 PM EDT today, August 11, 2022

1 year ago - GlobeNewsWire

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development ...

1 year ago - GlobeNewsWire